Lilly's Weight-Loss Franchise Drives 48% Quarterly Revenue Growth

Eli Lilly reported second-quarter 2026 revenue of $23.0 billion, up 48% from a year earlier. Mounjaro generated $9.94 billion and Zepbound produced $4.93 billion, making the two medicines the main engine of the quarter.

The growth came primarily from volume. Worldwide volume increased 60%, while realized prices fell 13%. In the United States, revenue rose 33% as volume increased 37% and realized prices declined 3%; Lilly said U.S. pricing would have fallen about 9% without adjustments to rebate and discount estimates.

Lilly raised full-year revenue guidance to $85 billion to $87 billion and committed another $4.5 billion to expand manufacturing in Indiana. That investment addresses a central constraint: demand is valuable only if the company can supply the market reliably. It also increases the need for careful execution across factories, launches and a growing pipeline.

The quarter strengthens the long-term case, but concentration is rising. Mounjaro and Zepbound together accounted for roughly two-thirds of revenue, based on the reported figures. Investors should track prescription volume, realized pricing, manufacturing output and pipeline progress, particularly as competition expands. The question is no longer whether demand exists; it is how much of that demand Lilly can convert into durable cash flow after pricing pressure and capacity spending.